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The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated
protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK
inhibition and the anti-proliferative effects of MEK inhibitors in melanoma cells. We suggest that Ki67 is a better biomarker for future
clinical studies.
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Constitutive activity of BRAF is known to be critical for the proli-
feration and survival of melanoma cells through the activation of
the RAF/MEK/ERK mitogen activated protein (MAP) kinase path-
way (Smalley, 2003). In light of this, a number of research groups
and pharmaceutical companies have begun to explore whether
targeting the BRAF/MEK pathway using shRNA and small mole-
cule inhibitors are viable therapeutic approaches (Hingorani et al,
2003; Karasarides et al, 2004; Sharma et al, 2005). In a recent series
of clinical trials of MEK inhibitors, investigators have used tumour
phospho-ERK (pERK) levels as a biomarker (Rinehart et al, 2004;
Lorusso et al, 2005). These studies have demonstrated that although
the MEK inhibitors, such as CI-1040 and PD0325901, inhibit
constitutive pERK activity within tumours there was little clinical
activity. The obvious conclusion is that these agents, like so many
others, are ineffective in the clinical setting. However, there is an
alternate explanation—the concentrations of MEK inhibitor re-
quired to inhibit the pathway are not correlated with those required
to inhibit cell growth. The link between pERK levels and inhibition
of growth has not been explored in melanoma. In the current study,
we have studied two MEK inhibitors and investigated the relation-
ship between the concentrations required to inhibit pERK and those
required to block the growth of a panel of melanoma cell lines.
MATERIALS AND METHODS
Cell culture
Human melanoma cells were isolated and cultured as described in
Smalley et al (2005).
Adherent cell proliferation analysis
Cells were treated with increasing concentrations of U0126
(Calbiochem, San Diego, CA, USA) (0.01–30mM) CI-1040 or
LY294002 in triplicate. Methylthiazolyldiphenyl-tetrazolium bro-
mide (MTT) assays were performed as described previously
(Smalley et al, 2006).
Western-blot analysis
Proteins were extracted and blotted as described in Smalley et al
(2005). Antibodies to pERK, total ERK (tERK), phospho-Akt and
Akt were from Cell Signaling Technology (Beverly, MA, USA).
Ki67 staining and quantification
Melanoma cells were prepared and stained as described previously
(Smalley et al, 2005). The primary antibody (anti-Ki67) was from
Zymed (San Franscisco, CA, USA). Cells were counterstained with
DAPI. Cells from six high-powered fields (60) were counted and
the number of Ki67-positive cells were expressed as a percentage of
total cell number (DAPI-positive).
CGH and BRAF/N-Ras sequencing
Comparative genomic hybridization (CGH) and mutation sequen-
cing were performed as described previously (Hoek et al, 2006). The
mutational status of the C8161 was reported in Sharma et al (2005).
Cell cycle analysis
Cell cycle analysis was performed after treatment with U0126 or
CI-1040 as described in Smalley et al (2005).
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Unless otherwise stated, all data show the mean of at least three
independent experiments. Where appropriate, the data show the
mean7s.e.
RESULTS
Most melanoma cell lines in our panel are BRAF V600E
mutant, N-Ras wt, c-Kit wt
The panel of seven melanoma cell lines were sequenced for BRAF,
N-Ras and c-Kit mutations (Table 1). The panel of cell lines chosen
represented the heterogeneity of mutations found in human
melanomas. Thus, most of the cell lines tested (5/7 or 70%)
harboured the V600E mutation in BRAF and were heterozygous for
the BRAF mutation. The two exceptions were C8161, which was
wild-type for both BRAF and N-Ras mutations (1/7 or 15%), and
SbCl2, which harbours the Codon-61 N-Ras mutation (1/7 or 15%).
None of the cell lines tested had mutations in c-Kit.
Lack of strict correlation between pERK inhibition and
reduced cell proliferation on a panel of melanoma cell lines
Treatment of melanoma cells with increasing concentrations of
U0126 led to inhibition of growth in all cell lines apart from the
SbCl2. There was a great deal of variation between the IC50 values
of U0126 on the melanoma cell lines that ranged from 300nM (for
WM35) to 10mM (for C8161) (Figure 1A). When we compared the
concentrations of U0126 needed to inhibit pERK levels with those
required to inhibit growth we saw little correlation. WM35 cells,
which had the lowest IC50 for growth inhibition (280nM), did not
show substantial reduction in pERK phosphorylation until 3mM
U0126 (Figure 1B). In the SbCl2 cell line, pERK was inhibited in the
absence of any effects upon cell growth. Whereas in the 1205Lu
cells, pERK was inhibited at 300nM U0126 and there was little
cell growth inhibition until 10mM U0126 (Figure 1B). To explore
whether these findings were the result of poor compound stability
in tissue culture, we treated the 1205Lu cells with U0126 for 48 and
72h and found that pERK levels were still blocked (data not
shown).
Increasing concentrations of U0126 increases G1 phase cell
cycle block and reduces Ki67 staining
Having demonstrated that pERK levels did not correlate with
inhibition of melanoma cell growth we next explored whether
there was a better correlation with expression of the cell
proliferation marker Ki67. Cell cycle analysis demonstrated that
increasing concentrations of U0126 reduced the proportion of cells
undergoing S-phase transition (Figure 2A). In these instances,
there was a closer link between reduction in S-phase fraction and
inhibition of growth (Figure 1A). Treatment of the melanoma cells
with U0126 reduced the percentage of cells staining positively for
Ki67 (Figure 2B,C). Quantification of these results revealed a
parallel between the concentrations of U0126 required to inhibit
cell growth and those required to reduce the fraction of Ki67-
positive cells (Figure 2C). In particular, a striking reduction of
Ki67 staining was noted for the WM35 cell line when treated with
300nM U0126 (Figure 2C), even though high pERK levels were
maintained (Figure 1B). In another prominent example, the SbCl2
cell line was found to be poorly responsive to the growth inhibitory
effects of U0126 (Figure 1A), even though pERK levels were
inhibited (Figure 1B). The lack of growth inhibition was reflected
in the levels of Ki67 staining, which were not diminished at the
highest concentration of U0126 (Figure 2C).
The MEK inhibitor CI-1040 has similar effects to that of
U0126 on pERK levels and cell growth
Although U0126 is a useful tool compound it is not clinically
relevant. To confirm that similar responses were seen with a
clinically relevant MEK inhibitor, we treated the C8161 and 1205Lu
cells with increasing concentrations of CI-1040. It was noted that
CI-1040 was more potent than U0126 at reducing the growth of the
C8161 and 1205Lu cell lines (Figure 3A). Again, like U0126, there
was a disconnection between the concentrations required to inhibit
growth and those to inhibit pERK levels (Figure 3B). For the
Table 1 Mutational profiles of BRAF, N-Ras and c-Kit in the panel of
melanoma cells
Cell line Lesion type BRAF N-Ras c-Kit BRAF digest
WM35 RGP V600E Wt wt HET
SBCl2 RGP Wt 61K wt Wt
WM793 VGP V600E Wt wt HET
1205Lu Met V600E Wt wt HET
451Lu Met V600E Wt wt HET
WM164 Met V600E Wt wt HET
C8161 Met Wt Wt ND ND
Wt, wild-type, ND, not determined, HET, heterozygous mutation.
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Figure 1 U0126 inhibits pERK and growth of a panel of melanoma cells
(A) Cells were treated with increasing concentrations of U0126 (1nM–
30mM) for 72h before being treated with MTT. Absorbances were read at
570nm and expressed as a percentage of control absorbance. Data show
the mean of three independent experiments 7s.e.m. (B) Reduction of
pERK activity following U0126 treatment. Cells were treated with U0126
for 24h and probed for pERK. Blots were stripped and reprobed for tERK
to demonstrate equal protein loading.
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complete loss of all pERK activity at 300nM. In the MTT assay,
there was only 33% reduction in 1205Lu cell growth at 300nM CI-
1040 (Figure 3A,B). Likewise, for the C8161 cells, all pERK activity
was blocked at 300nM CI-1040, which only corresponded to an
18% inhibition of cell growth (Figure 3A,B).
Inhibition of growth following PI3 kinase inhibitor
treatment correlates better with Ki67 staining than
inhibition of pAKT levels
To determine whether the results seen with MEK inhibition were
applicable to other signalling pathways active in melanoma, we
next focused upon the PI3K/Akt pathway. Treatment of melanoma
cells with increasing concentrations of the PI3 kinase inhibitor
LY294002 led to a concentration-dependent reduction in cell
growth (Figure 4A). Unlike U0126, there was little difference in the
IC50 for LY294002 between the cell lines, which was around 10mM.
Analysis of LY294002-mediated inhibition of pAkt levels showed
some variation between the cell lines. Nearly all of the pAkt was
inhibited at 300nM in the WM793 cell lines, whereas substantial
levels of pAkt were observed in the 1205Lu cells even after
treatment with 30mM LY294002 (Figure 4B). In agreement with our
results on U0126, there was a good correlation between LY294002-
mediated inhibition of cell growth (Figure 4A) and reduction in
Ki67 staining (Figure 4C).
DISCUSSION
Inhibitors which target the BRAF/MAP kinase pathway are
currently under intense preclinical and clinical investigation in
melanoma. One of the most common biomarkers used is the level
of pERK tumour biopsies. A number of recent studies have shown
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Figure 2 U0126 reduces S-phase fraction of melanoma cells and reduces Ki67 staining. (A) Cells treated with U0126 (30nM–30mM) for 24h were found
to undergo G1-phase cell cycle arrest. (B) Representative picture showing reduction in Ki67 staining of 1205Lu cells following U0126 (30mM) treatment. (C)
Quantification of Ki67 staining following U0126 treatment. Cells were treated with U0126 for 24h and stained for both Ki67 and DAPI. Data show mean of
three experiments where six high-power fields were counted. Ki67-positive cells were expressed as a percentage of total cell number (DAPI staining).
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sthat although pERK levels are indeed blocked in the lesions of
patients undergoing CI-1040 treatment, there is little clinical
benefit (Rinehart et al, 2004; Lorusso et al, 2005). This raises the
question of whether inhibition of pERK is correlated with the anti-
proliferative activities of the MEK inhibitors in this setting.
Here, we demonstrate that there is little parallel between the
inhibition of pERK and the anti-proliferative activity of two MEK
inhibitors in a panel of seven melanoma cell lines. Some cell lines,
such as WM35 and C8161, demonstrate reduced cell growth in the
relative absence of pERK inhibition, whereas others such as
1205Lu and SbCl2 demonstrate reduced pERK levels in the absence
of growth inhibition. There was no link between these discrepan-
cies and BRAF mutational status as nearly all (five out of seven) of
these melanoma lines harboured the V600E mutation in BRAF.
Others have demonstrated the presence of amplifications in
downstream components of the cell cycle machinery such as
cyclin D1 and CDK4, which may contribute to this observed
resistance (Curtin et al, 2005; Muthusamy et al, 2006). However,
CGH analysis of our panel of seven melanoma cell lines did not
reveal amplifications in cyclin D1 or CDK4 (data not shown). A
more probable explanation for these results is the high constitutive
activity in other signalling pathways that also drive melanoma
cells through the cell cycle, such as PI3K/Akt and Src/STAT3. It
is possible that there is some functional redundancy between the
mitogenic pathways in melanoma cells, so that inhibition of one
pathway, such as MAP kinase, may not adversely impact on
melanoma cell growth.
The effects of MEK inhibitors upon melanoma cells are mainly
cytostatic and we see little evidence of apoptosis induction. In line
with this observation, there is a better correlation with growth of
the U0126-induced anti-proliferative effects and the reduction of
Ki67 staining. As a similar correlation is seen using other putative
targeted therapy agents, such as PI3 kinase inhibitors, it is
therefore suggested that Ki67 staining of tumour sections could be
a general strategy for following the progress of targeted therapy
trials in melanoma. The implications of this study are clear;
although the use of phospho-specific antibody staining as a
biomarker may give some measure of target inhibition, it may not
necessarily correlate with the desired end biological effect (e.g.
growth inhibition or apoptosis). The planning of future clinical
trials would likely benefit from the inclusion of both a phospho-
specific signal transduction marker (such as pERK) and a
proliferation marker (such as Ki67) to allow a true measure of
treatment progress at the level of the tumour.
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Figure 4 LY294002-mediated inhibition of melanoma cell growth also correlates with reduced Ki67 staining (A) Cells were treated with increasing
concentrations of LY294002 (30nM–30mM) for 72h before being treated with MTT. Absorbances were read at 570nm and expressed as a percentage of
control absorbance. Data show the mean of three independent experiments 7s.e.m. (B) Reduction of phospho-Akt activity following LY249002 treatment.
Cells were treated with LY294002 for 24h and probed for pAkt. Blots were stripped and reprobed for total Akt to demonstrate equal protein loading. (C)
Quantification of Ki67 staining following LY294002 treatment. Cells were treated with LY294002 for 24h and stained for both Ki67 and DAPI. Data show
mean of three experiments where six high-power fields were counted. Ki67-positive cells were expressed as a percentage of total cell number (DAPI
staining).
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Figure 3 CI-1040 inhibits pERK and growth of two melanoma cell lines
(A) Cells were treated with increasing concentrations of CI-1040 (1nM–
10mM) for 72h before being treated with MTT. Absorbances were read at
570nm and expressed as a percentage of control absorbance. Data show
the mean of three independent experiments 7s.e.m. (B) Reduction of
pERK activity following CI-1040 treatment. Cells were treated with U0126
for 24h and probed for pERK. Blots were stripped and reprobed for tERK
to demonstrate equal protein loading.
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